BUSINESS

• Toho to Thoroughly Implement Drug Distribution GL, Focus on Cost-Cutting in Response to Impact of Drug Pricing Reform: Pres.
  March 20, 2018

• Takeda Bolstering Pitch for Inisync, Takecab in December: Anterio Ranking
  March 19, 2018

• Ethical Drug Sales Up 3.6% in January on AbbVie Hep C Drug, Seasonal Factors
  March 19, 2018

• EMA Accepts Filing for Xtandi’s CRPC Label Expansion
  March 19, 2018

• Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
  March 16, 2018

• Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
  March 16, 2018

• Rohto Wins Japan Exclusive Rights to JT’s JAK Inhibitor in Ophthalmology Field
  March 16, 2018

• Ono Exercises Option to Ink New Autoimmune Disease Deal with Merus
  March 15, 2018

• Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
  March 15, 2018

• Kaketsuken, Meiji-Kumamoto JV, Ink Deal on Share Transfer of New Company, with Completion Date Set on July 2
  March 15, 2018

• Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
  March 14, 2018

• Gilead Japan Rolling Up Its Sleeves for Foray into Oncology/Inflammation Market
  March 14, 2018

• Toyama Chemical Begins Patient Enrollment in Japan PIII Study of Avigan for SFTS
  March 13, 2018

• EA Pharma’s Livact Now Available in Thailand
  March 12, 2018

• Solifenacin Oral Suspension Approved in Europe for Pediatric NDO: Astellas
  March 12, 2018

• Costa Saroukos Tapped as Takeda’s Global CFO
  March 9, 2018

• Hiroo Ito Named New President of Actelion Pharmaceuticals Japan
  March 9, 2018

• Daiichi Sankyo’s ADC DS-8201 Enters Global PII Study for Colorectal Cancer
  March 9, 2018

• Aducanumab Trial Tweak Has No Impact on Probability of Success: Eisai CEO
  March 9, 2018

• Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
  March 9, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 394
• 395
• 396
• 397
• 398
• 399
• 400
• 401
• 402
• …
• Next ›
• 最終 »